ORIGINAL ARTICLE

DIFFERENCES OF TUMOR MASSES AND HEMOGLOBIN LEVELS IN CERVICAL CANCER SQUAMOUS CELL TYPE PATIENTS TREATED WITH COMBINATION OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY

R. Noviyani , K. Suwiyoga, I. Lesmana, R. Niruri, K. Tunas, and I N. G. Budiana

R. Noviyani
Department of Pharmacy, Faculty of Mathematics and Sciences Udayana University, Bali-Indonesia. Email: rini.noviyani@yahoo.co.id

K. Suwiyoga
Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University

I. Lesmana
Department of Pharmacy, Faculty of Mathematics and Sciences Udayana University, Bali-Indonesia

R. Niruri
Department of Pharmacy, Faculty of Mathematics and Sciences Udayana University, Bali-Indonesia

K. Tunas
Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University

and I N. G. Budiana
Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University
Online First: January 04, 2014 | Cite this Article
Noviyani, R., Suwiyoga, K., Lesmana, I., Niruri, R., Tunas, K., Budiana, a. 2014. DIFFERENCES OF TUMOR MASSES AND HEMOGLOBIN LEVELS IN CERVICAL CANCER SQUAMOUS CELL TYPE PATIENTS TREATED WITH COMBINATION OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY. Bali Medical Journal 3(1): 15-17. DOI:10.15562/bmj.v3i1.63


Background: Paclitaxel and carboplatin are standard operating procedure for chemotherapy treatment of cervical cancer squamous cell carcinoma at Sanglah General Hospital, Bali-Indonesia. Chemotherapy improves outcome of cancer treatment. However, chemotherapy brings also a variety of adverse effects and complications. This study aims to evaluate the therapeutic and adverse effects of chemotherapy in patients with squamous cell cervical cancer. Methods: This is a case study of six patients with cervical cancer underwent chemotherapy paclitaxel and carboplatin 3-series at Sanglah General Hospital, Bali-Indonesia during January to November 2013. The therapeutic effect of chemotherapy was assessed from cervical cancer tumor mass measured before and after chemotherapy 3-series. The adverse effect of chemotherapy was determined from hemoglobin levels measured before and after chemotherapy. Data were analyzed using a paired t-test with a level of confidence of 95% using the SPSS to find out the differences. Results: In this study we found that there is a difference between tumor mass pre and post 3 series chemotherapy within p < 0.05. In term of toxic effect, we also obtained that there were difference of hemoglobin between pre and post of treatment within p < 0.05. Conclusion: Paclitaxel carboplatin as a chemotherapy drug in patients with cervical cancer is highly recomended when seen from the effects of reduced tumor size, and has a low side effect of anemia (anemia grade 1).

No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0